Journal article
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
Abstract
BACKGROUND: Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drug's ability to prevent type 2 diabetes in individuals at high risk of developing the condition.
METHODS: 5269 adults aged 30 years or more with impaired fasting glucose or impaired glucose tolerance, or both, and no previous cardiovascular disease were recruited from 191 …
Authors
Gerstein HC; Yusuf S; Bosch J; Pogue J; Sheridan P; Dinccag N; Hanefeld M; Hoogwerf B; Laakso M; Mohan V
Journal
The Lancet, Vol. 368, No. 9541, pp. 1096–1105
Publisher
Elsevier
Publication Date
9 2006
DOI
10.1016/s0140-6736(06)69420-8
ISSN
0140-6736